This is Part I of our special report on the state of immunotherapy in the public markets. This report looks at promising anticancer immunotherapy technologies, and the major issues in bringing these technologies to the general public.
Crystal Research Associates, LLC, an independent equity research firm, announced today a partnership with OneMedPlace to broaden services and provide additional visibility to research clients via the integrated OneMedPlace platform.
HealthTech Conference 2012, on October 26th in San Francisco, is a single day summit covering the most important issues in this burgeoning sector. OneMedRadio spoke with Anne Degheest, Managing Director and Founder of HealthTech Capital, about conference programming, and the unique investment opportunity in the sector.
Tatyana Chorny answered a series of questions written by marcus evans before the forthcoming Medical Device Safety Monitoring and Reporting Conference, January 17-18, 2013 in Las Vegas, NV. Tatyana shares her thoughts on timely reporting and regulatory compliance.
Implandata Ophthalmic Products GmbH, a German medical device start-up developing a technology for monitoring chronic eye diseases such as glaucoma, will be featured among the private companies presenting at the 6th Annual OneMedForum, January 7-9 in San Francisco.
Colby Pharmaceutical Company (Colby), a privately held San Jose, CA based biopharmaceutical company, announced that it has acquired Othera Pharmaceuticals Inc. (Othera) of Conshohocken, PA.
OneMedPlace will be covering the European Tech Tour Association’s 3rd Annual Medtech Summit, taking place October 16-17 in Lausanne, Switzerland. Stay tuned for on-site coverage of programming and showcased companies, as well as a wrap-up of the event!
San Diego-based Freedom Meditech, Inc., a privately-held medical device company focused on commercialization of ophthalmic technologies for the detection of disease and management of patient health, last week announced it had secured a $2MM line of credit from Silicon Valley Bank.
The threat of infection in hospital and other treatment facilities have dramatically increased over the last few years. Antibiotics and other therapies have become impotent against certain pathogens and infections, increasing the need for research funding for creating new antibiotics. These three companies have the potential to solve a significant unmet medical need.
Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE), a clinical-stage biopharmaceutical company developing drugs for sexual dysfunction, inflammatory diseases and ophthalmological conditions has announced a manufacturing agreement with drug delivery maker Enthypharm Ltd for Zertane, Ampio’s drug for the treatment of premature ejaculation (PE).
Copyright © 2024 | WordPress Theme by MH Themes